SAW PALMETTO TINCTURE - LIQ 0.25 GM/ML 250 MG
SAW PALMETTO : 250 MG · DIN 02161095 · HOLISTA HEALTH (CANADA) INC.
Health Canada status: CANCELLED POST MARKET
What is SAW PALMETTO TINCTURE - LIQ 0.25 GM/ML?
SAW PALMETTO TINCTURE - LIQ 0.25 GM/ML 250 MG contains SAW PALMETTO : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 02161095, held by HOLISTA HEALTH (CANADA) INC., supplied as LIQUID for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 01-Aug-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02161095 |
|---|---|
| Brand name | SAW PALMETTO TINCTURE - LIQ 0.25 GM/ML |
| Generic / active ingredient | SAW PALMETTO : 250 MG |
| Manufacturer | HOLISTA HEALTH (CANADA) INC. |
| Strength | 250 MG |
| Dosage form | LIQUID |
| Route of administration | ORAL |
| Schedule | NON-PRESCRIPTION DRUGS |
| ATC code | S01JA02 ROSE BENGAL SODIUM |
| AHFS class | 92:01.00* ; See footnote |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 01-Aug-2001 |
| Original market date | 1996-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02161095 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2161095 |
| Brand name | SAW PALMETTO TINCTURE - LIQ 0.25 GM/ML |
| Active ingredient / INN | SAW PALMETTO : 250 MG |
| ATC code | S01JA02 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S01 |
| AHFS class | 92:01.00* ; See footnote |
| Health Canada schedule | NON-PRESCRIPTION DRUGS |
| Biosimilar biologic | No |
| Market authorization holder | HOLISTA HEALTH (CANADA) INC. |
Which pack is which?
| Strength on the label | 250 MG |
|---|---|
| Dosage form | LIQUID |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code S01JA02 ROSE BENGAL SODIUM. 0 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ODAN-ROSE | 10 MG | SOLUTION | ODAN LABORATORIES LTD | DORMANT | DIN 00832170 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.